Selected research
Market Outlook & Growth Opportunities
Global Anti-amyloid Therapy Market Outlook and Growth Opportunities 2026
Market perspective
The global Anti-amyloid Therapy market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.
The North America market for Anti-amyloid Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Anti-amyloid Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Anti-amyloid Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
In China, the Anti-amyloid Therapy market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Major global companies in the Anti-amyloid Therapy market include Eisai, Eli Lilly and Biogen, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Anti-amyloid Therapy market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Anti-amyloid Therapy and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Anti-amyloid Therapy sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Anti-amyloid Therapy market size, projected growth trends, production technologies, key applications, and end-use industries.
Anti-amyloid Therapy Segment by Company
Eisai
Eli Lilly
Biogen
Anti-amyloid Therapy Segment by Type
Lecanemab
Donanemab
Anti-amyloid Therapy Segment by Application
Hospital
Clinic
Other
Anti-amyloid Therapy Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global Anti-amyloid Therapy status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Anti-amyloid Therapy market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Anti-amyloid Therapy significant trends, drivers, influence factors in global and regions.
6. To analyze Anti-amyloid Therapy competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-amyloid Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Anti-amyloid Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-amyloid Therapy.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Anti-amyloid Therapy market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Anti-amyloid Therapy industry.
Chapter 3: Detailed analysis of Anti-amyloid Therapy manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Anti-amyloid Therapy in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Anti-amyloid Therapy in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
More report detail
Tables and figures
List of Tables
Table 1. Anti-amyloid Therapy Industry Trends
Table 2. Anti-amyloid Therapy Industry Drivers
Table 3. Anti-amyloid Therapy Industry Opportunities and Challenges
Table 4. Anti-amyloid Therapy Industry Restraints
Table 5. Global Anti-amyloid Therapy Revenue by Company (US$ Million) & (2021-2026)
Table 6. Global Anti-amyloid Therapy Revenue Share by Company (2021-2026)
Table 7. Global Anti-amyloid Therapy Sales Volume by Company (K Units) & (2021-2026)
Table 8. Global Anti-amyloid Therapy Sales Volume Share by Company (2021-2026)
Table 9. Global Anti-amyloid Therapy Average Price (US$/Unit) of Company (2021-2026)
Table 10. Global Anti-amyloid Therapy Company Ranking, (2024-2026) & (USD Million)
Table 11. Global Anti-amyloid Therapy Key Company Manufacturing Base & Headquarters
Table 12. Global Anti-amyloid Therapy Company, Product Type & Application
Table 13. Global Anti-amyloid Therapy Company Establishment Date
Table 14. Global Company Market Concentration Ratio (CR5 and HHI)
Table 15. Global Anti-amyloid Therapy by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025)
Table 16. Mergers & Acquisitions, Expansion
Table 17. Significant Companies of Lecanemab
Table 18. Significant Companies of Donanemab
Table 19. Global Anti-amyloid Therapy Sales Volume by Type 2021 VS 2025 VS 2032 (K Units)
Table 20. Global Anti-amyloid Therapy Sales Volume by Type (2021-2026) & (K Units)
Table 21. Global Anti-amyloid Therapy Sales Volume by Type (2027-2032) & (K Units)
Table 22. Global Anti-amyloid Therapy Sales Volume Share by Type (2021-2026)
Table 23. Global Anti-amyloid Therapy Sales Volume Share by Type (2027-2032)
Table 24. Global Anti-amyloid Therapy Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million)
Table 25. Global Anti-amyloid Therapy Sales Value by Type (2021-2026) & (US$ Million)
Table 26. Global Anti-amyloid Therapy Sales Value by Type (2027-2032) & (US$ Million)
Table 27. Global Anti-amyloid Therapy Sales Value Share by Type (2021-2026)
Table 28. Global Anti-amyloid Therapy Sales Value Share by Type (2027-2032)
Table 29. Significant Companies of Hospital
Table 30. Significant Companies of Clinic
Table 31. Significant Companies of Other
Table 32. Global Anti-amyloid Therapy Sales Volume by Application 2021 VS 2025 VS 2032 (K Units)
Table 33. Global Anti-amyloid Therapy Sales Volume by Application (2021-2026) & (K Units)
Table 34. Global Anti-amyloid Therapy Sales Volume by Application (2027-2032) & (K Units)
Table 35. Global Anti-amyloid Therapy Sales Volume Share by Application (2021-2026)
Table 36. Global Anti-amyloid Therapy Sales Volume Share by Application (2027-2032)
Table 37. Global Anti-amyloid Therapy Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million)
Table 38. Global Anti-amyloid Therapy Sales Value by Application (2021-2026) & (US$ Million)
Table 39. Global Anti-amyloid Therapy Sales Value by Application (2027-2032) & (US$ Million)
Table 40. Global Anti-amyloid Therapy Sales Value Share by Application (2021-2026)
Table 41. Global Anti-amyloid Therapy Sales Value Share by Application (2027-2032)
Table 42. Global Anti-amyloid Therapy Sales by Region: 2021 VS 2025 VS 2032 (K Units)
Table 43. Global Anti-amyloid Therapy Sales by Region (2021-2026) & (K Units)
Table 44. Global Anti-amyloid Therapy Sales Market Share by Region (2021-2026)
Table 45. Global Anti-amyloid Therapy Sales by Region (2027-2032) & (K Units)
Table 46. Global Anti-amyloid Therapy Sales Market Share by Region (2027-2032)
Table 47. Global Anti-amyloid Therapy Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million)
Table 48. Global Anti-amyloid Therapy Sales Value by Region (2021-2026) & (US$ Million)
Table 49. Global Anti-amyloid Therapy Sales Value Share by Region (2021-2026)
Table 50. Global Anti-amyloid Therapy Sales Value by Region (2027-2032) & (US$ Million)
Table 51. Global Anti-amyloid Therapy Sales Value Share by Region (2027-2032)
Table 52. Global Anti-amyloid Therapy Market Average Price (US$/Unit) by Region (2021-2026)
Table 53. Global Anti-amyloid Therapy Market Average Price (US$/Unit) by Region (2027-2032)
Table 54. Global Anti-amyloid Therapy Sales by Country: 2021 VS 2025 VS 2032 (K Units)
Table 55. Global Anti-amyloid Therapy Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 56. Global Anti-amyloid Therapy Sales by Country (2021-2026) & (K Units)
Table 57. Global Anti-amyloid Therapy Sales Market Share by Country (2021-2026)
Table 58. Global Anti-amyloid Therapy Sales by Country (2027-2032) & (K Units)
Table 59. Global Anti-amyloid Therapy Sales Market Share by Country (2027-2032)
Table 60. Global Anti-amyloid Therapy Sales Value by Country (2021-2026) & (US$ Million)
Table 61. Global Anti-amyloid Therapy Sales Value Market Share by Country (2021-2026)
Table 62. Global Anti-amyloid Therapy Sales Value by Country (2027-2032) & (US$ Million)
Table 63. Global Anti-amyloid Therapy Sales Value Market Share by Country (2027-2032)
Table 64. Eisai Company Information
Table 65. Eisai Business Overview
Table 66. Eisai Anti-amyloid Therapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 67. Eisai Anti-amyloid Therapy Product Portfolio
Table 68. Eisai Recent Development
Table 69. Eli Lilly Company Information
Table 70. Eli Lilly Business Overview
Table 71. Eli Lilly Anti-amyloid Therapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 72. Eli Lilly Anti-amyloid Therapy Product Portfolio
Table 73. Eli Lilly Recent Development
Table 74. Biogen Company Information
Table 75. Biogen Business Overview
Table 76. Biogen Anti-amyloid Therapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 77. Biogen Anti-amyloid Therapy Product Portfolio
Table 78. Biogen Recent Development
Table 79. Key Raw Materials
Table 80. Raw Materials Key Suppliers
Table 81. Anti-amyloid Therapy Distributors List
Table 82. Anti-amyloid Therapy Customers List
Table 83. Research Programs/Design for This Report
Table 84. Authors List of This Report
Table 85. Secondary Sources
Table 86. Primary Sources
List of Figures
Figure 1. Anti-amyloid Therapy Product Image
Figure 2. Global Anti-amyloid Therapy Sales Value (US$ Million), 2021 VS 2025 VS 2032
Figure 3. Global Anti-amyloid Therapy Sales Value (2021-2032) & (US$ Million)
Figure 4. Global Anti-amyloid Therapy Sales (2021-2032) & (K Units)
Figure 5. Global Anti-amyloid Therapy Sales Average Price (US$/Unit) & (2021-2032)
Figure 6. Global Anti-amyloid Therapy Company Revenue Ranking in 2025 (US$ Million)
Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million)
Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
Figure 9. Lecanemab Image
Figure 10. Donanemab Image
Figure 11. Global Anti-amyloid Therapy Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units)
Figure 12. Global Anti-amyloid Therapy Sales Volume Share 2021 VS 2025 VS 2032
Figure 13. Global Anti-amyloid Therapy Sales Volume Share by Type (2021-2032)
Figure 14. Global Anti-amyloid Therapy Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million)
Figure 15. Global Anti-amyloid Therapy Sales Value Share 2021 VS 2025 VS 2032
Figure 16. Global Anti-amyloid Therapy Sales Value Share by Type (2021-2032)
Figure 17. Hospital Image
Figure 18. Clinic Image
Figure 19. Other Image
Figure 20. Global Anti-amyloid Therapy Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units)
Figure 21. Global Anti-amyloid Therapy Sales Volume Share 2021 VS 2025 VS 2032
Figure 22. Global Anti-amyloid Therapy Sales Volume Share by Application (2021-2032)
Figure 23. Global Anti-amyloid Therapy Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million)
Figure 24. Global Anti-amyloid Therapy Sales Value Share 2021 VS 2025 VS 2032
Figure 25. Global Anti-amyloid Therapy Sales Value Share by Application (2021-2032)
Figure 26. Global Anti-amyloid Therapy Sales by Region: 2021 VS 2025 VS 2032 (K Units)
Figure 27. Global Anti-amyloid Therapy Sales Market Share by Region: 2021 VS 2025 VS 2032
Figure 28. Global Anti-amyloid Therapy Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million)
Figure 29. Global Anti-amyloid Therapy Sales Value Share by Region: 2021 VS 2025 VS 2032
Figure 30. North America Anti-amyloid Therapy Sales Value (2021-2032) & (US$ Million)
Figure 31. North America Anti-amyloid Therapy Sales Value Share by Country (%), 2025 VS 2032
Figure 32. Europe Anti-amyloid Therapy Sales Value (2021-2032) & (US$ Million)
Figure 33. Europe Anti-amyloid Therapy Sales Value Share by Country (%), 2025 VS 2032
Figure 34. Asia-Pacific Anti-amyloid Therapy Sales Value (2021-2032) & (US$ Million)
Figure 35. Asia-Pacific Anti-amyloid Therapy Sales Value Share by Country (%), 2025 VS 2032
Figure 36. South America Anti-amyloid Therapy Sales Value (2021-2032) & (US$ Million)
Figure 37. South America Anti-amyloid Therapy Sales Value Share by Country (%), 2025 VS 2032
Figure 38. Middle East & Africa Anti-amyloid Therapy Sales Value (2021-2032) & (US$ Million)
Figure 39. Middle East & Africa Anti-amyloid Therapy Sales Value Share by Country (%), 2025 VS 2032
Figure 40. USA Anti-amyloid Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 41. USA Anti-amyloid Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 42. USA Anti-amyloid Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 43. Canada Anti-amyloid Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 44. Canada Anti-amyloid Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 45. Canada Anti-amyloid Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 46. Mexico Anti-amyloid Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 47. Mexico Anti-amyloid Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 48. Mexico Anti-amyloid Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 49. Germany Anti-amyloid Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 50. Germany Anti-amyloid Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 51. Germany Anti-amyloid Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 52. France Anti-amyloid Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 53. France Anti-amyloid Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 54. France Anti-amyloid Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 55. U.K. Anti-amyloid Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 56. U.K. Anti-amyloid Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 57. U.K. Anti-amyloid Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 58. Italy Anti-amyloid Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 59. Italy Anti-amyloid Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 60. Italy Anti-amyloid Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 61. Spain Anti-amyloid Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 62. Spain Anti-amyloid Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 63. Spain Anti-amyloid Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 64. Russia Anti-amyloid Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 65. Russia Anti-amyloid Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 66. Russia Anti-amyloid Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 67. Netherlands Anti-amyloid Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 68. Netherlands Anti-amyloid Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 69. Netherlands Anti-amyloid Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 70. Nordic Countries Anti-amyloid Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 71. Nordic Countries Anti-amyloid Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 72. Nordic Countries Anti-amyloid Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 73. China Anti-amyloid Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 74. China Anti-amyloid Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 75. China Anti-amyloid Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 76. Japan Anti-amyloid Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 77. Japan Anti-amyloid Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 78. Japan Anti-amyloid Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 79. South Korea Anti-amyloid Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 80. South Korea Anti-amyloid Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 81. South Korea Anti-amyloid Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 82. India Anti-amyloid Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 83. India Anti-amyloid Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 84. India Anti-amyloid Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 85. Australia Anti-amyloid Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 86. Australia Anti-amyloid Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 87. Australia Anti-amyloid Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 88. Southeast Asia Anti-amyloid Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 89. Southeast Asia Anti-amyloid Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 90. Southeast Asia Anti-amyloid Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 91. Brazil Anti-amyloid Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 92. Brazil Anti-amyloid Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 93. Brazil Anti-amyloid Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 94. Argentina Anti-amyloid Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 95. Argentina Anti-amyloid Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 96. Argentina Anti-amyloid Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 97. Chile Anti-amyloid Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 98. Chile Anti-amyloid Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 99. Chile Anti-amyloid Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 100. Colombia Anti-amyloid Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 101. Colombia Anti-amyloid Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 102. Colombia Anti-amyloid Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 103. Peru Anti-amyloid Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 104. Peru Anti-amyloid Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 105. Peru Anti-amyloid Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 106. Saudi Arabia Anti-amyloid Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 107. Saudi Arabia Anti-amyloid Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 108. Saudi Arabia Anti-amyloid Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 109. Israel Anti-amyloid Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 110. Israel Arabia Anti-amyloid Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 111. Israel Arabia Anti-amyloid Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 112. UAE Anti-amyloid Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 113. UAE Anti-amyloid Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 114. UAE Anti-amyloid Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 115. Turkey Anti-amyloid Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 116. Turkey Anti-amyloid Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 117. Turkey Anti-amyloid Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 118. Iran Anti-amyloid Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 119. Iran Anti-amyloid Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 120. Iran Anti-amyloid Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 121. Egypt Anti-amyloid Therapy Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 122. Egypt Anti-amyloid Therapy Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 123. Egypt Anti-amyloid Therapy Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 124. Anti-amyloid Therapy Value Chain
Figure 125. Manufacturing Cost Structure
Figure 126. Anti-amyloid Therapy Sales Mode & Process
Figure 127. Direct Comparison with Distribution Share
Figure 128. Distributors Profiles
Figure 129. Years Considered
Figure 130. Research Process
Figure 131. Key Executives Interviewed
Scope & coverage.
Types
- Lecanemab
- Donanemab
Applications
- Hospital
- Clinic
- Other
Companies covered
- Eisai
- Eli Lilly
- Biogen
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.2.1 Global Anti-amyloid Therapy Sales Value (2021-2032)
- 1.2.2 Global Anti-amyloid Therapy Sales Volume (2021-2032)
- 1.2.3 Global Anti-amyloid Therapy Sales Average Price (2021-2032)
- 1.3 Assumptions and Limitations
- 1.4 Study Goals and Objectives
2 Anti-amyloid Therapy Market Dynamics
- 2.1 Anti-amyloid Therapy Industry Trends
- 2.2 Anti-amyloid Therapy Industry Drivers
- 2.3 Anti-amyloid Therapy Industry Opportunities and Challenges
- 2.4 Anti-amyloid Therapy Industry Restraints
3 Anti-amyloid Therapy Market by Company
- 3.1 Global Anti-amyloid Therapy Company Revenue Ranking in 2025
- 3.2 Global Anti-amyloid Therapy Revenue by Company (2021-2026)
- 3.3 Global Anti-amyloid Therapy Sales Volume by Company (2021-2026)
- 3.4 Global Anti-amyloid Therapy Average Price by Company (2021-2026)
- 3.5 Global Anti-amyloid Therapy Company Ranking (2024-2026)
- 3.6 Global Anti-amyloid Therapy Company Manufacturing Base and Headquarters
- 3.7 Global Anti-amyloid Therapy Company Product Type and Application
- 3.8 Global Anti-amyloid Therapy Company Establishment Date
- 3.9 Market Competitive Analysis
- 3.9.1 Global Anti-amyloid Therapy Market Concentration Ratio (CR5 and HHI)
- 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
- 3.9.3 2025 Anti-amyloid Therapy Tier 1, Tier 2, and Tier 3 Companies
- 3.10 Mergers and Acquisitions Expansion
4 Anti-amyloid Therapy Market by Type
- 4.1 Anti-amyloid Therapy Type Introduction
- 4.1.1 Lecanemab
- 4.1.2 Donanemab
- 4.2 Global Anti-amyloid Therapy Sales Volume by Type
- 4.2.1 Global Anti-amyloid Therapy Sales Volume by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Anti-amyloid Therapy Sales Volume by Type (2021-2032)
- 4.2.3 Global Anti-amyloid Therapy Sales Volume Share by Type (2021-2032)
- 4.3 Global Anti-amyloid Therapy Sales Value by Type
- 4.3.1 Global Anti-amyloid Therapy Sales Value by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Anti-amyloid Therapy Sales Value by Type (2021-2032)
- 4.3.3 Global Anti-amyloid Therapy Sales Value Share by Type (2021-2032)
5 Anti-amyloid Therapy Market by Application
- 5.1 Anti-amyloid Therapy Application Introduction
- 5.1.1 Hospital
- 5.1.2 Clinic
- 5.1.3 Other
- 5.2 Global Anti-amyloid Therapy Sales Volume by Application
- 5.2.1 Global Anti-amyloid Therapy Sales Volume by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Anti-amyloid Therapy Sales Volume by Application (2021-2032)
- 5.2.3 Global Anti-amyloid Therapy Sales Volume Share by Application (2021-2032)
- 5.3 Global Anti-amyloid Therapy Sales Value by Application
- 5.3.1 Global Anti-amyloid Therapy Sales Value by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Anti-amyloid Therapy Sales Value by Application (2021-2032)
- 5.3.3 Global Anti-amyloid Therapy Sales Value Share by Application (2021-2032)
6 Anti-amyloid Therapy Regional Sales and Value Analysis
- 6.1 Global Anti-amyloid Therapy Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Anti-amyloid Therapy Sales by Region (2021-2032)
- 6.2.1 Global Anti-amyloid Therapy Sales by Region: 2021-2026
- 6.2.2 Global Anti-amyloid Therapy Sales by Region (2027-2032)
- 6.3 Global Anti-amyloid Therapy Sales Value by Region: 2021 VS 2025 VS 2032
- 6.4 Global Anti-amyloid Therapy Sales Value by Region (2021-2032)
- 6.4.1 Global Anti-amyloid Therapy Sales Value by Region: 2021-2026
- 6.4.2 Global Anti-amyloid Therapy Sales Value by Region (2027-2032)
- 6.5 Global Anti-amyloid Therapy Market Price Analysis by Region (2021-2026)
- 6.6 North America
- 6.6.1 North America Anti-amyloid Therapy Sales Value (2021-2032)
- 6.6.2 North America Anti-amyloid Therapy Sales Value Share by Country, 2025 VS 2032
- 6.7 Europe
- 6.7.1 Europe Anti-amyloid Therapy Sales Value (2021-2032)
- 6.7.2 Europe Anti-amyloid Therapy Sales Value Share by Country, 2025 VS 2032
- 6.8 Asia-Pacific
- 6.8.1 Asia-Pacific Anti-amyloid Therapy Sales Value (2021-2032)
- 6.8.2 Asia-Pacific Anti-amyloid Therapy Sales Value Share by Country, 2025 VS 2032
- 6.9 South America
- 6.9.1 South America Anti-amyloid Therapy Sales Value (2021-2032)
- 6.9.2 South America Anti-amyloid Therapy Sales Value Share by Country, 2025 VS 2032
- 6.10 Middle East & Africa
- 6.10.1 Middle East & Africa Anti-amyloid Therapy Sales Value (2021-2032)
- 6.10.2 Middle East & Africa Anti-amyloid Therapy Sales Value Share by Country, 2025 VS 2032
7 Anti-amyloid Therapy Country-level Sales and Value Analysis
- 7.1 Global Anti-amyloid Therapy Sales by Country: 2021 VS 2025 VS 2032
- 7.2 Global Anti-amyloid Therapy Sales Value by Country: 2021 VS 2025 VS 2032
- 7.3 Global Anti-amyloid Therapy Sales by Country (2021-2032)
- 7.3.1 Global Anti-amyloid Therapy Sales by Country (2021-2026)
- 7.3.2 Global Anti-amyloid Therapy Sales by Country (2027-2032)
- 7.4 Global Anti-amyloid Therapy Sales Value by Country (2021-2032)
- 7.4.1 Global Anti-amyloid Therapy Sales Value by Country (2021-2026)
- 7.4.2 Global Anti-amyloid Therapy Sales Value by Country (2027-2032)
- 7.5 USA
- 7.5.1 USA Anti-amyloid Therapy Sales Value Growth Rate (2021-2032)
- 7.5.2 USA Anti-amyloid Therapy Sales Value Share by Type, 2025 VS 2032
- 7.5.3 USA Anti-amyloid Therapy Sales Value Share by Application, 2025 VS 2032
- 7.6 Canada
- 7.6.1 Canada Anti-amyloid Therapy Sales Value Growth Rate (2021-2032)
- 7.6.2 Canada Anti-amyloid Therapy Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Canada Anti-amyloid Therapy Sales Value Share by Application, 2025 VS 2032
- 7.7 Mexico
- 7.6.1 Mexico Anti-amyloid Therapy Sales Value Growth Rate (2021-2032)
- 7.6.2 Mexico Anti-amyloid Therapy Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Mexico Anti-amyloid Therapy Sales Value Share by Application, 2025 VS 2032
- 7.8 Germany
- 7.8.1 Germany Anti-amyloid Therapy Sales Value Growth Rate (2021-2032)
- 7.8.2 Germany Anti-amyloid Therapy Sales Value Share by Type, 2025 VS 2032
- 7.8.3 Germany Anti-amyloid Therapy Sales Value Share by Application, 2025 VS 2032
- 7.9 France
- 7.9.1 France Anti-amyloid Therapy Sales Value Growth Rate (2021-2032)
- 7.9.2 France Anti-amyloid Therapy Sales Value Share by Type, 2025 VS 2032
- 7.9.3 France Anti-amyloid Therapy Sales Value Share by Application, 2025 VS 2032
- 7.10 U.K.
- 7.10.1 U.K. Anti-amyloid Therapy Sales Value Growth Rate (2021-2032)
- 7.10.2 U.K. Anti-amyloid Therapy Sales Value Share by Type, 2025 VS 2032
- 7.10.3 U.K. Anti-amyloid Therapy Sales Value Share by Application, 2025 VS 2032
- 7.11 Italy
- 7.11.1 Italy Anti-amyloid Therapy Sales Value Growth Rate (2021-2032)
- 7.11.2 Italy Anti-amyloid Therapy Sales Value Share by Type, 2025 VS 2032
- 7.11.3 Italy Anti-amyloid Therapy Sales Value Share by Application, 2025 VS 2032
- 7.12 Spain
- 7.12.1 Spain Anti-amyloid Therapy Sales Value Growth Rate (2021-2032)
- 7.12.2 Spain Anti-amyloid Therapy Sales Value Share by Type, 2025 VS 2032
- 7.12.3 Spain Anti-amyloid Therapy Sales Value Share by Application, 2025 VS 2032
- 7.13 Russia
- 7.13.1 Russia Anti-amyloid Therapy Sales Value Growth Rate (2021-2032)
- 7.13.2 Russia Anti-amyloid Therapy Sales Value Share by Type, 2025 VS 2032
- 7.13.3 Russia Anti-amyloid Therapy Sales Value Share by Application, 2025 VS 2032
- 7.14 Netherlands
- 7.14.1 Netherlands Anti-amyloid Therapy Sales Value Growth Rate (2021-2032)
- 7.14.2 Netherlands Anti-amyloid Therapy Sales Value Share by Type, 2025 VS 2032
- 7.14.3 Netherlands Anti-amyloid Therapy Sales Value Share by Application, 2025 VS 2032
- 7.15 Nordic Countries
- 7.15.1 Nordic Countries Anti-amyloid Therapy Sales Value Growth Rate (2021-2032)
- 7.15.2 Nordic Countries Anti-amyloid Therapy Sales Value Share by Type, 2025 VS 2032
- 7.15.3 Nordic Countries Anti-amyloid Therapy Sales Value Share by Application, 2025 VS 2032
- 7.16 China
- 7.16.1 China Anti-amyloid Therapy Sales Value Growth Rate (2021-2032)
- 7.16.2 China Anti-amyloid Therapy Sales Value Share by Type, 2025 VS 2032
- 7.16.3 China Anti-amyloid Therapy Sales Value Share by Application, 2025 VS 2032
- 7.17 Japan
- 7.17.1 Japan Anti-amyloid Therapy Sales Value Growth Rate (2021-2032)
- 7.17.2 Japan Anti-amyloid Therapy Sales Value Share by Type, 2025 VS 2032
- 7.17.3 Japan Anti-amyloid Therapy Sales Value Share by Application, 2025 VS 2032
- 7.18 South Korea
- 7.18.1 South Korea Anti-amyloid Therapy Sales Value Growth Rate (2021-2032)
- 7.18.2 South Korea Anti-amyloid Therapy Sales Value Share by Type, 2025 VS 2032
- 7.18.3 South Korea Anti-amyloid Therapy Sales Value Share by Application, 2025 VS 2032
- 7.19 India
- 7.19.1 India Anti-amyloid Therapy Sales Value Growth Rate (2021-2032)
- 7.19.2 India Anti-amyloid Therapy Sales Value Share by Type, 2025 VS 2032
- 7.19.3 India Anti-amyloid Therapy Sales Value Share by Application, 2025 VS 2032
- 7.20 Australia
- 7.20.1 Australia Anti-amyloid Therapy Sales Value Growth Rate (2021-2032)
- 7.20.2 Australia Anti-amyloid Therapy Sales Value Share by Type, 2025 VS 2032
- 7.20.3 Australia Anti-amyloid Therapy Sales Value Share by Application, 2025 VS 2032
- 7.21 Southeast Asia
- 7.21.1 Southeast Asia Anti-amyloid Therapy Sales Value Growth Rate (2021-2032)
- 7.21.2 Southeast Asia Anti-amyloid Therapy Sales Value Share by Type, 2025 VS 2032
- 7.21.3 Southeast Asia Anti-amyloid Therapy Sales Value Share by Application, 2025 VS 2032
- 7.22 Brazil
- 7.22.1 Brazil Anti-amyloid Therapy Sales Value Growth Rate (2021-2032)
- 7.22.2 Brazil Anti-amyloid Therapy Sales Value Share by Type, 2025 VS 2032
- 7.22.3 Brazil Anti-amyloid Therapy Sales Value Share by Application, 2025 VS 2032
- 7.23 Argentina
- 7.23.1 Argentina Anti-amyloid Therapy Sales Value Growth Rate (2021-2032)
- 7.23.2 Argentina Anti-amyloid Therapy Sales Value Share by Type, 2025 VS 2032
- 7.23.3 Argentina Anti-amyloid Therapy Sales Value Share by Application, 2025 VS 2032
- 7.24 Chile
- 7.24.1 Chile Anti-amyloid Therapy Sales Value Growth Rate (2021-2032)
- 7.24.2 Chile Anti-amyloid Therapy Sales Value Share by Type, 2025 VS 2032
- 7.24.3 Chile Anti-amyloid Therapy Sales Value Share by Application, 2025 VS 2032
- 7.25 Colombia
- 7.25.1 Colombia Anti-amyloid Therapy Sales Value Growth Rate (2021-2032)
- 7.25.2 Colombia Anti-amyloid Therapy Sales Value Share by Type, 2025 VS 2032
- 7.25.3 Colombia Anti-amyloid Therapy Sales Value Share by Application, 2025 VS 2032
- 7.26 Peru
- 7.26.1 Peru Anti-amyloid Therapy Sales Value Growth Rate (2021-2032)
- 7.26.2 Peru Anti-amyloid Therapy Sales Value Share by Type, 2025 VS 2032
- 7.26.3 Peru Anti-amyloid Therapy Sales Value Share by Application, 2025 VS 2032
- 7.27 Saudi Arabia
- 7.27.1 Saudi Arabia Anti-amyloid Therapy Sales Value Growth Rate (2021-2032)
- 7.27.2 Saudi Arabia Anti-amyloid Therapy Sales Value Share by Type, 2025 VS 2032
- 7.27.3 Saudi Arabia Anti-amyloid Therapy Sales Value Share by Application, 2025 VS 2032
- 7.28 Israel
- 7.28.1 Israel Anti-amyloid Therapy Sales Value Growth Rate (2021-2032)
- 7.28.2 Israel Anti-amyloid Therapy Sales Value Share by Type, 2025 VS 2032
- 7.28.3 Israel Anti-amyloid Therapy Sales Value Share by Application, 2025 VS 2032
- 7.29 UAE
- 7.29.1 UAE Anti-amyloid Therapy Sales Value Growth Rate (2021-2032)
- 7.29.2 UAE Anti-amyloid Therapy Sales Value Share by Type, 2025 VS 2032
- 7.29.3 UAE Anti-amyloid Therapy Sales Value Share by Application, 2025 VS 2032
- 7.30 Turkey
- 7.30.1 Turkey Anti-amyloid Therapy Sales Value Growth Rate (2021-2032)
- 7.30.2 Turkey Anti-amyloid Therapy Sales Value Share by Type, 2025 VS 2032
- 7.30.3 Turkey Anti-amyloid Therapy Sales Value Share by Application, 2025 VS 2032
- 7.31 Iran
- 7.31.1 Iran Anti-amyloid Therapy Sales Value Growth Rate (2021-2032)
- 7.31.2 Iran Anti-amyloid Therapy Sales Value Share by Type, 2025 VS 2032
- 7.31.3 Iran Anti-amyloid Therapy Sales Value Share by Application, 2025 VS 2032
- 7.32 Egypt
- 7.32.1 Egypt Anti-amyloid Therapy Sales Value Growth Rate (2021-2032)
- 7.32.2 Egypt Anti-amyloid Therapy Sales Value Share by Type, 2025 VS 2032
- 7.32.3 Egypt Anti-amyloid Therapy Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
- 8.1 Eisai
- 8.1.1 Eisai Company Information
- 8.1.2 Eisai Business Overview
- 8.1.3 Eisai Anti-amyloid Therapy Sales, Value and Gross Margin (2021-2026)
- 8.1.4 Eisai Anti-amyloid Therapy Product Portfolio
- 8.1.5 Eisai Recent Developments
- 8.2 Eli Lilly
- 8.2.1 Eli Lilly Company Information
- 8.2.2 Eli Lilly Business Overview
- 8.2.3 Eli Lilly Anti-amyloid Therapy Sales, Value and Gross Margin (2021-2026)
- 8.2.4 Eli Lilly Anti-amyloid Therapy Product Portfolio
- 8.2.5 Eli Lilly Recent Developments
- 8.3 Biogen
- 8.3.1 Biogen Company Information
- 8.3.2 Biogen Business Overview
- 8.3.3 Biogen Anti-amyloid Therapy Sales, Value and Gross Margin (2021-2026)
- 8.3.4 Biogen Anti-amyloid Therapy Product Portfolio
- 8.3.5 Biogen Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Anti-amyloid Therapy Value Chain Analysis
- 9.1.1 Anti-amyloid Therapy Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Anti-amyloid Therapy Sales Mode & Process
- 9.2 Anti-amyloid Therapy Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Anti-amyloid Therapy Distributors
- 9.2.3 Anti-amyloid Therapy Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
$4,250USD
Buy nowPDF by email within 3–5 working days after payment confirmation.
Talk to an analyst